Sensorion Announces Poster Presentation at the “Société Internationale d’Otoneurologie” Symposium
June 3, 2019
Presentation of SENS-111 phase 2 study protocol in Acute Unilateral
Vestibulopathy (AUV)
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering
clinical-stage biopharmaceutical company which specializes in the
development of novel therapies to restore, treat and prevent inner ear
diseases such as hearing loss, tinnitus and vertigo, presented a poster
at the “Société internationale d’Otoneurologie” (SIO) in Venice, Italy
from May 30th to June 1st, 2019.
This poster entitled “A multicenter, randomized, double-blind,
placebo-controlled study to assess the efficacy and safety of 2 dose
regimens of orally administered SENS-111 (100 mg and 200 mg) given
during 4 days in patients suffering from Acute Unilateral Vestibulopathy
(AUV)” covers the study design and assessments, the main inclusion and
exclusion criteria and an update on the study progress.
Eighty-six patients have been enrolled in the study so far and, the
results are expected, as already announced, at the end of 2019.
About Seliforant
Seliforant (formerly SENS-111) is the first
representative candidate of the histamine type 4 receptor antagonist
class to be tested for the symptomatic treatment of vertigo crises.
Displaying a neuromodulation effect of the sensorineural inner ear cell
function, Seliforant is a small molecule that can be taken orally or via
a standard injection, and is currently in a separate Phase 2 clinical
trial, being conducted in the United States, Europe, Israel and South
Korea.
About Sensorion
Sensorion is a pioneering clinical-stage
biopharmaceutical company, which specializes in the development of novel
therapies to restore, treat and prevent inner ear diseases such as
hearing loss, vertigo and tinnitus. Our clinical-stage portfolio
includes two phase 2 products: Seliforant (SENS-111) in acute unilateral
vestibulopathy and Arazasetron (SENS-401) for sudden sensorineural
hearing loss (SSNHL). We have built a unique R&D technology platform to
expand our understanding of the pathophysiology and etiology of inner
ear diseases enabling us to select the best targets and modalities for
drug candidates. We also identify biomarkers to improve diagnosis and
treatment of these underserved illnesses.
We are uniquely placed through our platforms and pipeline of potential
therapeutics to make a lasting positive impact on hundreds of thousands
of people with inner ear related disorders; a significant global unmet
need in medicine today.
Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN
Disclaimer
This press release contains certain
forward-looking statements concerning Sensorion and its business. Such
forward looking statements are based on assumptions that Sensorion
considers to be reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
‘Document de référence’ registration document filed with the ‘Autorité
des Marchés Financiers’ (AMF French Financial Market Authority) on
September 7th, 2017 under n°R.17-062 and to the development of economic
conditions, financial markets and the markets in which Sensorion
operates. The forward-looking statements contained in this press release
are also subject to risks not yet known to Sensorion or not currently
considered material by Sensorion. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance or
achievements of Sensorion to be materially different from such
forward-looking statements.
This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of an
offer to purchase or subscribe for, Sensorion shares in any country. The
communication of this press release in certain countries may constitute
a violation of local laws and regulations. Any recipient of this press
release must inform oneself of any such local restrictions and comply
therewith.
Contacts
Sensorion
Nawal Ouzren
CEO
[email protected]
Tel:
+33 467 207 730
Catherine Leveau
Financial communication
[email protected]
Tel:
+33 467 207 730